PharmiWeb Today Story
UCB has announced a definitive agreement to acquire Neurona Therapeutics in a deal valued at up to $1.15 billion, strengthening its position in epilepsy and advancing its move into regenerative medicine. The transaction includes an upfront payment of $650 million, with up to $500 million in milestone payments.
The acquisition brings Neurona’s lead asset, NRTX-1001, into UCB’s portfolio. This investigational neuronal cell therapy is currently being evaluated in Phase I/II trials for drug-resistant mesial temporal lobe epilepsy, a common and difficult-to-treat form of focal epilepsy.
NRTX-1001 uses pluripotent stem cell-derived interneurons designed to restore neural circuit balance by delivering GABA-producing cells directly into the brain. The single-dose approach aims to provide durable seizure reduction and potentially modify disease progression rather than simply manage symptoms.
The deal reflects UCB’s long-standing focus on epilepsy, building on more than 30 years of innovation in the field. It also marks a strategic expansion into advanced and regenerative therapies, aligning with the company’s ambition to address high unmet needs and deliver disease-modifying treatments.
Subject to regulatory approvals, the transaction is expected to close in the second quarter of 2026
Read More...
Articles
Featured Events
-
Pharmaceutical Manufacturing & Packaging Congress…
28-Jun-2021 - 29-Jun-2021 -
6th CAR-TCR Summit
30-Aug-2021 - 02-Sep-2021 -
PM Society: Measuring Patient Engagement: Opening…
12-Oct-2022 - 12-Oct-2022 -
Finding the Value in Strategic Outsourcing Partner…
22-Feb-2023 - 22-Feb-2023 -
Genomics and Precision Medicine Expo
23-May-2023 - 24-May-2023 -
PharmaMarketing USA Summit
08-Feb-2024 - 09-Feb-2024
News
-
Leerink Partners Initiates Medincell’s Coverage wi…
21-Apr-2026 -
Uqora® Launches Cutting-Edge Urinary Health Produc…
21-Apr-2026 -
Pfizer Showcases Oncology Innovation and Next-Gene…
21-Apr-2026 -
Genentech’s Enspryng (Satralizumab) Reduces Risk o…
21-Apr-2026 -
Bicycle Therapeutics Announces Oral and Poster Pre…
21-Apr-2026 -
Immunome Announces Oral Presentation of Phase 3 RI…
21-Apr-2026